1. RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia.
- Author
-
Xiao, Jinyan, Xie, Jundan, Zhou, Biqi, Liu, Yujie, Lu, Jing, Jiang, Airui, Yao, Hong, Qiu, Qiaocheng, Ding, Zixuan, Xue, Shengli, Tang, Xiaowen, Qiu, Huiying, Chen, Suning, Shen, Hongjie, Wu, Depei, and Xu, Yang
- Subjects
ACUTE myeloid leukemia ,HEMATOPOIETIC stem cell transplantation ,FRAMESHIFT mutation ,PROPENSITY score matching ,GAIN-of-function mutations ,MISSENSE mutation - Abstract
We retrospectively explored the prognostic impact of DAT mutations at diagnosis in 122 RUNX1
mut AML patients. RUNX1 missense mutation was dominant in the RUNT domain, and frameshift mutation was dominant in the TAD domain. DAT mutations occurred in 38.5% of RUNX1mut AML. After propensity score matching, DATpos patients had worse two-year relapse-free survival (RFS) than DATneg patients (p =.041). Moreover, RUNX1high (VAF ≥ 37.6%) patients showed poorer two-year overall survival (OS) and RFS than RUNX1low (VAF < 37.6%) patients (OS, p =.033; RFS, p =.027), especially in the RUNX1high DATpos group. Additionally, multivariate analysis confirmed that DAT mutations at diagnosis were an independent adverse factor for RFS. There were no significant differences in two-year OS and RFS between DATpos and DATneg patients or between RUNX1high and RUNX1low patients who undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Collectively, DAT mutations at diagnosis were adverse factors for RFS, and allo-HSCT could likely improve the poor outcomes of these patients. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF